credit – Lab DB

Pharmaceutical R&D

Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109

Teuku Ryan Apr 7, 2026 0

Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…

Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109

YOU MAY HAVE MISSED

Breakthrough High-Resolution Imaging Technique Unlocks Hidden Complexities of Mouse Bone Marrow for Advanced Disease Research

A novel immune organ inside the skull directs brain defense and may offer a new way to fight brain cancer and neurodegenerative disease

The oral exposure challenge in PROTACs: What drug developers need to solve early

Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape